LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

NCT ID: NCT04031872

Last Updated: 2025-09-05

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-01
• Study Completion Date: 2020-01-01

Brief Summary

Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC. Part II is designed to obtain proof of principle of the LY3200882 plus capecitabine combination in patients with chemo-resistant CRC. The combination of LY3200882 plus capecitabine will be given as second line therapy in the phase II part of this study.

Patients with chemotherapy resistant activated TGF-β signature-like tumors will have received a fluoropyrimidine (5FU or capecitabine) in the first line of chemotherapy, usually combined with oxaliplatin and, depending upon local hospital preferences or national guidelines, also bevacizumab, or cetuximab/panitumumab if the tumor is KRAS wild type. Addition of LY3200882 to capecitabine should thus result in reversal of unresponsiveness, which is the first step in exploring this concept in the clinic. Capecitabine can be used as single agent in advanced CRC and is thus attractive for this study concept. If proof of principle is achieved also other tumor types can be explored with this genetic makeup, such as non-small cell lung cancer (NSCLC) in second line of treatment after platinum doublet therapy in first line, usually cisplatin/carboplatin-pemetrexed in non-squamous and cisplatin/carboplatin-gemcitabine or cisplatin/carboplatin-paclitaxel in squamous type NSCLC.

Conditions

Colorectal Cancer Metastatic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TGF-beta activated colorectal cancer

TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine

Group Type: EXPERIMENTAL

LY3200882

Intervention Type: DRUG

Combination treatment with LY3200882 and capecitabine

Interventions

LY3200882

Combination treatment with LY3200882 and capecitabine

Intervention Type: DRUG

Other Intervention Names

Capecitabine

Eligibility Criteria

Inclusion Criteria

1. Histological or cytological proof of CRC;

2. Disease progression or relapse upon at least one line of treatment for advanced CRC with fluoropyrimidine containing chemotherapy as single agent or in combination (combinations with oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab are allowed);

3. Written documentation of activated TGF-β signature-like gene signature, as determined by the validated assay of Agendia;

4. Age ≥ 18 years;

5. Able and willing to give written informed consent;

6. WHO performance status of ≤ 1;

7. LVEF ≥ 55%;

8. Able and willing to undergo blood sampling for PK and PD analysis;

9. Able and willing to undergo tumor biopsies before start, during treatment and at the end of treatment

10. Life expectancy ≥ 3 months allowing adequate follow up of toxicity evaluation and anti-tumor activity;

11. Evaluable disease according to RECIST 1.1 criteria (measurable disease for the phase II part; evaluable disease is sufficient for the phase I part);

12. Minimal acceptable safety laboratory values

1. ANC of ≥ 1.5 x 109 /L

2. Platelet count of ≥ 100 x 109 /L

3. Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ALAT and ASAT ≤ 3.0 x ULN, or ALAT and ASAT ≤ 5 x ULN in patients with liver metastases

4. Renal function as defined by serum creatinine ≤1.5 x ULN

5. Creatinine clearance ≥ 50 ml/min (by Cockcroft-Gault formula or MDRD);

13. Negative pregnancy test (urine or serum) for female patients with childbearing potential.

Exclusion Criteria

1. Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment;

2. Known or suspected dihydropirimidine dehydrogenase deficit (Mutant for DPD*2A genotype, 1236 GA genotype, 1679TG genotype and 2846A>T genotype);

3. Symptomatic or untreated leptomeningeal disease;

4. Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid therapy are allowed to enrol. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT (<21 days before start of treatment) completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids;

5. History of cardiac disease, including myocardial infarction within 6 months before study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension, major cardiac abnormalities, a predisposition for developing aneurysms including family history of aneurysms, Marfan syndrome, bicuspid aortic valve, or evidence of damage to the large vessels of the heart.

6. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LY3200882 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection);

7. Woman who are pregnant or breast feeding;

8. Radio- or chemotherapy within the last 2 weeks prior to receiving the first dose of investigational treatment. Palliative radiation (1x 8Gy) is allowed;

9. Patients who have undergone any major surgery within the last 2 weeks prior to starting study drug or who would not have fully recovered from previous surgery;

10. Active infection requiring systemic antibiotics or uncontrolled infectious disease;

11. Patients with a known history of hepatitis B or C or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;

12. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study;

13. Known hypersensitivity to one of the study drugs or excipients.

14. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of <1% per year (when used consistently and correctly) during the treatment period and for at least 90 days after the last dose of LY3200882 and/or capecitabine. More information is available in section 5.2.4.

15. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined in section 5.2.4.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vall d'Hebron Institute of Oncology

OTHER

Sponsor Role: collaborator

Agendia

INDUSTRY

Sponsor Role: collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

Sponsor Role: collaborator

Azienda Ospedaliera Niguarda Cà Granda

OTHER

Sponsor Role: collaborator

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

Sponsor Role: collaborator

University of Campania Luigi Vanvitelli

OTHER

Sponsor Role: collaborator

University of Turin, Italy

OTHER

Sponsor Role: collaborator

Eli Lilly and Company

INDUSTRY

Sponsor Role: collaborator

Catalan Institute of Health

OTHER_GOV

Sponsor Role: collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role: collaborator

The Netherlands Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

J Tabernero, Prof

Role: PRINCIPAL_INVESTIGATOR

VHIO

R Bernards, Prof

Role: PRINCIPAL_INVESTIGATOR

NKI-AvL

R Salazar, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

ICO

S Siena, Prof

Role: PRINCIPAL_INVESTIGATOR

ONCG

A Cervantes, Prof

Role: PRINCIPAL_INVESTIGATOR

Instituto de Investigacion Sanitaria INCLIVA

F Ciardello, Prof

Role: PRINCIPAL_INVESTIGATOR

UNINA2

A Bardelli, Prof

Role: PRINCIPAL_INVESTIGATOR

UNITO

S Tejpar, Prof

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Other Identifiers

M19TGA

Identifier Type: -

Identifier Source: org_study_id